These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 3917460)

  • 1. Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man.
    Vance ML; Kaiser DL; Evans WS; Thorner MO; Furlanetto R; Rivier J; Vale W; Perisutti G; Frohman LA
    J Clin Endocrinol Metab; 1985 Feb; 60(2):370-5. PubMed ID: 3917460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH.
    Vance ML; Kaiser DL; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1986 Mar; 62(3):591-4. PubMed ID: 3080467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short term continuous intravenous infusion of growth hormone (GH) inhibits GH-releasing hormone-induced GH secretion: a time-dependent effect.
    Rosenthal SM; Kaplan SL; Grumbach MM
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1101-5. PubMed ID: 2498383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pulsatile administration, continuous infusion, and diurnal variation on the growth hormone (GH) response to GH-releasing hormone in normal men.
    Hulse JA; Rosenthal SM; Cuttler L; Kaplan SL; Grumbach MM
    J Clin Endocrinol Metab; 1986 Oct; 63(4):872-8. PubMed ID: 3091629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.
    Vance ML; Kaiser DL; Evans WS; Furlanetto R; Vale W; Rivier J; Thorner MO
    J Clin Invest; 1985 May; 75(5):1584-90. PubMed ID: 2860126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.
    Vance ML; Kaiser DL; Martha PM; Furlanetto R; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1989 Jan; 68(1):22-8. PubMed ID: 2491864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone-releasing hormone infusion in patients with active acromegaly.
    Losa M; Chiodini PG; Liuzzi A; König A; Müller OA; Schopohl J; von Werder K
    J Clin Endocrinol Metab; 1986 Jul; 63(1):88-93. PubMed ID: 3086362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
    Huhn WC; Hartman ML; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1993 May; 76(5):1202-8. PubMed ID: 8496311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone responses to continuous infusions of growth hormone-releasing hormone.
    Gelato MC; Rittmaster RS; Pescovitz OH; Nicoletti MC; Nixon WE; D'Agata R; Loriaux DL; Merriam GR
    J Clin Endocrinol Metab; 1985 Aug; 61(2):223-8. PubMed ID: 3924946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone-stimulated GH secretion in normal man.
    Vance ML; Kaiser DL; Frohman LA; Rivier J; Vale WW; Thorner MO
    J Clin Endocrinol Metab; 1987 Jun; 64(6):1136-41. PubMed ID: 3553220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion.
    Kelijman M; Frohman LA
    J Clin Endocrinol Metab; 1990 Jul; 71(1):157-63. PubMed ID: 1973420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion.
    Gelato MC; Oldfield E; Loriaux DL; Merriam GR
    J Clin Endocrinol Metab; 1990 Sep; 71(3):585-90. PubMed ID: 2118536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: partial response attenuation.
    DeBell WK; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1312-6. PubMed ID: 2026752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nocturnal continuous infusion of growth hormone (GH)-releasing hormone results in a dose-dependent accentuation of episodic GH secretion in normal men.
    Sassolas G; Garry J; Cohen R; Bastuji H; Vermeulen E; Cabrera P; Roussel B; Jouvet M
    J Clin Endocrinol Metab; 1986 Oct; 63(4):1016-22. PubMed ID: 3091627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man.
    Giustina A; Girelli A; Doga M; Bodini C; Bossoni S; Romanelli G; Wehrenberg WB
    J Clin Endocrinol Metab; 1990 Sep; 71(3):580-4. PubMed ID: 2118535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study.
    Jaffe CA; Turgeon DK; Friberg RD; Watkins PB; Barkan AL
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3321-6. PubMed ID: 7593445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor. Intermittent secretion or response attenuation.
    Webb CB; Vance ML; Thorner MO; Perisutti G; Thominet J; Rivier J; Vale W; Frohman LA
    J Clin Invest; 1984 Jul; 74(1):96-103. PubMed ID: 6429198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly.
    Losa M; Schopohl J; König A; Müller OA; von Werder K
    J Clin Endocrinol Metab; 1986 Aug; 63(2):475-80. PubMed ID: 3088026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The decrease in growth hormone (GH) response after repeated stimulation with GH-releasing hormone is partly caused by an elevation of somatostatin tonus.
    Reichardt B; Schrader M; Mojto J; Mehltretter G; Müller OA; Schopohl J
    J Clin Endocrinol Metab; 1996 May; 81(5):1994-8. PubMed ID: 8626871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.